Comment on "Enhanced Half-Life Recombinant Factor VIII Concentrates for Hemophilia A: Insights from Pivotal and Extension Studies"
Semin Thromb Hemost
.
2022 Mar;48(2):251-252.
doi: 10.1055/s-0041-1736573.
Epub 2021 Nov 8.
Authors
Regina Horneff
1
,
Linda Bystrická
1
,
Elena Santagostino
1
,
Stefan Lethagen
1
,
Sandra Casiano
2
Affiliations
1
Global Medical and Scientific Affairs, Swedish Orphan Biovitrum AB, Stockholm, Sweden.
2
Global Medical Affairs, Sanofi Genzyme, Cambridge, Massachusetts.
PMID:
34749400
DOI:
10.1055/s-0041-1736573
No abstract available
Publication types
Letter
Comment
MeSH terms
Factor IX
Factor VIII* / therapeutic use
Half-Life
Hemophilia A* / drug therapy
Humans
Substances
Factor VIII
Factor IX